Volovitz B, Nussinovitch M, Finkelstein Y, Harel L, Varsano I
Asthma Clinic, Department of Pediatrics C, Schneider Children's Medical Center of Israel, Petach Tikva.
Clin Pediatr (Phila). 2001 Feb;40(2):79-86. doi: 10.1177/000992280104000203.
Many clinicians advise their patients to increase the dose of inhaled corticosteroids during acute asthma exacerbations, without strong clinical evidence supporting this treatment. This study investigates the effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home. The study population consisted of children with mild intermittent, mild and moderate persistent asthma aged 1 to 14 years who were treated in our outpatient clinic with inhaled budesonide for 1 year. After participating in an asthma education session, the parents were instructed to initiate treatment with inhaled budesonide at the first signs of asthma exacerbation, starting with 200 to 400 microg budesonide, in combination with beta-2 agonists 4 times a day and followed by a decrease in the dose in 4 to 8 days. Asthma status and peak expiratory flow rates were measured in the 3 monthly follow-up visits. Only children who complied with the treatment regimen and came for follow-up visits regularly were included in the final analysis. One hundred fifty children used our treatment protocol with inhaled budesonide to control their asthma attacks. Clinical improvement of asthma symptoms was achieved after a mean of 1.8 +/- 0.7 days from the beginning of treatment. The parents were able to control 94% of the 1,061 episodes of asthma exacerbation occurring during a cumulative follow-up period of 239 years. In the 3-month period before enrollment, 101 children (67%) had used oral corticosteroids to control their asthma attacks and 50 (33%) were hospitalized. During the entire follow-up period, only 11 children (7%) used oral corticosteroids, and none of the children were hospitalized. The present study demonstrates that children with asthma can control their exacerbations at home using inhaled corticosteroids (budesonide). Treatment, starting with relatively high doses followed by a rapid reduction in dose over 4-8 days, resulted in a decrease in the use of oral steroids and in hospitalization. To achieve good results, patient compliance is essential.
许多临床医生建议患者在急性哮喘发作期间增加吸入性糖皮质激素的剂量,但并无有力的临床证据支持这种治疗方法。本研究调查了吸入性糖皮质激素在家中控制儿童急性哮喘发作的有效性。研究对象为年龄在1至14岁之间、患有轻度间歇性、轻度和中度持续性哮喘的儿童,他们在我们的门诊接受吸入布地奈德治疗1年。在参加哮喘教育课程后,指导家长在哮喘发作的最初迹象出现时开始使用吸入布地奈德治疗,起始剂量为200至400微克布地奈德,与β-2激动剂联合使用,每日4次,随后在4至8天内减少剂量。在每月3次的随访中测量哮喘状态和呼气峰值流速。最终分析仅纳入了遵守治疗方案并定期前来随访的儿童。150名儿童采用我们的吸入布地奈德治疗方案来控制哮喘发作。从治疗开始起,平均1.8±0.7天后哮喘症状得到临床改善。在累计239年的随访期内发生的1061次哮喘发作中,家长能够控制其中的94%。在入组前的3个月期间,101名儿童(67%)曾使用口服糖皮质激素来控制哮喘发作,50名(33%)曾住院治疗。在整个随访期间,只有11名儿童(7%)使用了口服糖皮质激素,且无儿童住院。本研究表明,哮喘儿童可以在家中使用吸入性糖皮质激素(布地奈德)控制发作。治疗从相对高剂量开始,随后在4至8天内迅速减少剂量,这导致了口服类固醇药物的使用减少以及住院率降低。为取得良好效果,患者的依从性至关重要。